COL18A1 and anemia (phenotype): In safety analysis, severe adverse reactions in the rh‐endostatin group included leukopenia in 14 cases (25.9%), granulocytopenia in 9 cases (16.7%), anemia in 3 cases (5.6%), thrombocytopenia in 3 cases (5.6%), and nausea in 3 cases (5.6%).